Empowering the Lymphatics
Sector
MedTech
Company
Emerging MedTech
Therapeutic Area
Oncology and Immunology
Treatment Modality
Drug-Device
Product Stage
Clinical
Expertise
Scientific
Sofusa is a pioneering drug–device platform that targets the lymphatic system to enhance immune modulation and drug absorption, with applications spanning immunology and oncology. The platform was designed to address a fundamental bottleneck in therapeutic delivery — bypassing first-pass metabolism and restoring lymphatic flow to enable improved efficacy at lower doses. Our engagement began with a focus on two high-impact indications: rheumatoid arthritis (RA) and cutaneous T-cell lymphoma (CTCL). These areas, marked by unmet needs and limited innovation in delivery mechanisms, offered a strategic proving ground for Sofusa’s technology.
Situation
Sofusa is a pioneering drug–device platform that targets the lymphatic system to enhance immune modulation and drug absorption, with applications spanning immunology and oncology. The platform was designed to address a fundamental bottleneck in therapeutic delivery — bypassing first-pass metabolism and restoring lymphatic flow to enable improved efficacy at lower doses. Our engagement began with a focus on two high-impact indications: rheumatoid arthritis (RA) and cutaneous T-cell lymphoma (CTCL). These areas, marked by unmet needs and limited innovation in delivery mechanisms, offered a strategic proving ground for Sofusa’s technology.
Situation
Approach
The strategic process began with a deep analysis of market dynamics, clinical data, and competitive positioning across target disease areas. Rheumatology presented the largest addressable opportunity, with RA treatment paradigms constrained by systemic delivery’s dose-limiting toxicities. In oncology, CTCL’s fragmented treatment landscape offered room for a differentiated, patient-friendly therapy with strong safety and tolerability. We translated Sofusa’s technical advantages into a clinically resonant and commercially relevant narrative — emphasizing its ability to regenerate lymphatic function, increase local drug concentration, and reduce systemic exposure. Parallel efforts in investor relations and partnering positioned Sofusa as not just a device innovator, but as a category creator in lymphatic-targeted medicine.
Approach
Results
This integrated approach catalyzed measurable outcomes. Sofusa secured $80M in growth capital, accelerating late-stage clinical programs and expanding its BD pipeline in both autoimmune and oncology markets. Its refined positioning drew interest from top-tier pharmaceutical partners, paving the way for co-development discussions and licensing opportunities. Today, Sofusa stands as a recognized leader in lymphatic-targeted therapeutics, with a platform capable of transforming treatment delivery across a wide spectrum of immune-mediated diseases.
Situation
Sofusa is a pioneering drug–device platform that targets the lymphatic system to enhance immune modulation and drug absorption, with applications spanning immunology and oncology. The platform was designed to address a fundamental bottleneck in therapeutic delivery — bypassing first-pass metabolism and restoring lymphatic flow to enable improved efficacy at lower doses. Our engagement began with a focus on two high-impact indications: rheumatoid arthritis (RA) and cutaneous T-cell lymphoma (CTCL). These areas, marked by unmet needs and limited innovation in delivery mechanisms, offered a strategic proving ground for Sofusa’s technology.
Approach
The strategic process began with a deep analysis of market dynamics, clinical data, and competitive positioning across target disease areas. Rheumatology presented the largest addressable opportunity, with RA treatment paradigms constrained by systemic delivery’s dose-limiting toxicities. In oncology, CTCL’s fragmented treatment landscape offered room for a differentiated, patient-friendly therapy with strong safety and tolerability. We translated Sofusa’s technical advantages into a clinically resonant and commercially relevant narrative — emphasizing its ability to regenerate lymphatic function, increase local drug concentration, and reduce systemic exposure. Parallel efforts in investor relations and partnering positioned Sofusa as not just a device innovator, but as a category creator in lymphatic-targeted medicine.
Results
This integrated approach catalyzed measurable outcomes. Sofusa secured $80M in growth capital, accelerating late-stage clinical programs and expanding its BD pipeline in both autoimmune and oncology markets. Its refined positioning drew interest from top-tier pharmaceutical partners, paving the way for co-development discussions and licensing opportunities. Today, Sofusa stands as a recognized leader in lymphatic-targeted therapeutics, with a platform capable of transforming treatment delivery across a wide spectrum of immune-mediated diseases.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to start a conversation.
Work With Us
Advance biology to belief—sharper, faster, and leaner.
Connect with our Biography team to start a conversation.